AXDX - Accelerate Diagnostics Inc Stock Price, Fair Value and News

0.90USD+0.01 (+1.12%)Delayed as of 23 Apr 2024, 10:56 am ET

Market Summary

USD0.90+0.01

Delayedas of 23 Apr 2024, 10:56 am

1.12%

AXDX Stock Price

View Fullscreen

AXDX RSI Chart

AXDX Valuation

Market Cap

19.3M

Price/Earnings (Trailing)

-0.31

Price/Sales (Trailing)

1.6

EV/EBITDA

-0.12

Price/Free Cashflow

-0.48

AXDX Price/Sales (Trailing)

AXDX Profitability

EBT Margin

-503.94%

Return on Equity

309.83%

Return on Assets

-196.45%

Free Cashflow Yield

-208.47%

AXDX Fundamentals

AXDX Revenue

Revenue (TTM)

12.1M

Rev. Growth (Yr)

1.82%

Rev. Growth (Qtr)

-8.24%

AXDX Earnings

Earnings (TTM)

-61.6M

Earnings Growth (Yr)

11.03%

Earnings Growth (Qtr)

-1.5K%

Breaking Down AXDX Revenue

52 Week Range

0.91

(Low)(High)

Last 30 days

-8.1%

Last 90 days

-32.1%

Trailing 12 Months

-86.8%

How does AXDX drawdown profile look like?

AXDX Financial Health

Current Ratio

2.03

AXDX Investor Care

Shares Dilution (1Y)

117.45%

Diluted EPS (TTM)

-5.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.6M	11.7M	12.0M	12.1M
2022	12.2M	13.3M	13.1M	12.8M
2021	11.3M	12.0M	11.5M	11.8M
2020	9.9M	10.2M	11.5M	11.2M
2019	6.6M	6.7M	7.6M	9.3M
2018	4.4M	5.4M	6.0M	5.7M
2017	613.0K	1.3M	2.1M	4.2M
2016	224.0K	226.0K	229.0K	246.0K
2015	122.0K	127.0K	132.0K	75.0K
2014	46.0K	52.0K	55.0K	122.0K
2013	80.0K	41.0K	48.2K	48.0K
2012	241.7K	238.8K	236.0K	158.0K
2011	0	0	244.5K	243.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Accelerate Diagnostics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	phillips jack	acquired	-	-	59,928	chief executive officer
Apr 17, 2024	phillips jack	sold	-20,853	0.78	-26,735	chief executive officer
Apr 12, 2024	phillips jack	acquired	-	-	59,928	chief executive officer
Apr 12, 2024	phillips jack	sold	-22,828	0.86	-26,545	chief executive officer
Apr 09, 2024	mertz larry michael	sold	-12,166	0.87	-13,984	chief technology officer
Apr 09, 2024	patience david	acquired	-	-	37,468	chief financial officer
Apr 09, 2024	mertz larry michael	acquired	-	-	40,633	chief technology officer
Apr 09, 2024	patience david	sold	-11,567	0.87	-13,296	chief financial officer
Apr 04, 2024	phillips jack	sold	-13,980	0.88	-15,887	chief executive officer
Apr 04, 2024	mertz larry michael	acquired	-	-	2,866	chief technology officer

Which funds bought or sold AXDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	unchanged	-	-622	210	-%
Apr 18, 2024	Ironwood Financial, llc	new	-	19,615	19,615	-%
Apr 17, 2024	GRIFFIN ASSET MANAGEMENT, INC.	added	11.03	-3,440,610	1,340,710	0.16%
Apr 15, 2024	THOMPSON INVESTMENT MANAGEMENT, INC.	unchanged	-	-30,443	10,286	-%
Apr 05, 2024	CWM, LLC	reduced	-28.9	-1,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.18	-540,630	1,202,020	-%
Mar 04, 2024	Northwest Bank & Trust Co	new	-	548	548	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	60,548	60,548	-%
Feb 14, 2024	Cladis Investment Advisory, LLC	reduced	-12.31	-83,599	124,264	0.11%
Feb 14, 2024	Royal Bank of Canada	added	12.2	-11,000	37,000	-%

Are Funds Buying or Selling AXDX?

Are funds buying AXDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXDX

No. of Funds

Unveiling Accelerate Diagnostics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 05, 2024	griffin asset management, inc.	8.4%	1,219,724	SC 13G
Jun 20, 2023	schuler jack w	40.6%	58,012,207	SC 13D/A
Jun 20, 2023	indaba capital management, l.p.	9.9%	15,972,241	SC 13D
Jun 08, 2023	schuler jack w	19.99%	20,260,952	SC 13D/A
Feb 24, 2022	feinberg larry n	4.97%	3,257,503	SC 13G/A
Feb 11, 2022	feinberg larry n	5.53%	3,627,549	SC 13G/A
Dec 03, 2021	schuler jack w	26.4%	18,409,240	SC 13D/A
Oct 05, 2021	schuler jack w	25.7%	17,186,959	SC 13D/A
Feb 16, 2021	feinberg larry n	6.67%	3,806,139	SC 13G/A
Feb 12, 2021	credit suisse ag/	3.10%	1,765,390	SC 13G/A

Recent SEC filings of Accelerate Diagnostics Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 11, 2024	DEF 14A	DEF 14A
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Accelerate Diagnostics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.8B	40.1B	-3.17%	-4.12%	32.46	4.63	-8.12%	-17.45%
BDX	67.6B	19.5B	-4.91%	-10.36%	53.86	3.47	4.02%	-22.04%
ALGN	22.6B	3.9B	-5.82%	-15.30%	50.76	5.85	3.42%	23.09%
BAX	20.5B	14.8B	-3.67%	-10.80%	7.72	1.39	2.12%	209.17%
MID-CAP
ATR	9.3B	3.5B	-0.90%	16.36%	32.56	2.66	4.97%	18.89%
HSIC	9.3B	12.3B	-1.49%	-14.91%	22.25	0.75	-2.44%	-22.68%
BIO	8.2B	2.7B	-20.12%	-40.09%	-12.83	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.30%	-26.11%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-2.14%	10.95%	-561.72	9.3	33.86%	89.83%
PDCO	2.3B	6.6B	-4.88%	-5.43%	11.99	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.12%	-21.63%	-1.88	0.4	7.73%	-1066.14%
ANIK	385.4M	166.7M	2.04%	-4.03%	-4.66	2.31	6.67%	-456.34%
ANGO	250.7M	324.0M	16.79%	-29.66%	-1.3	0.77	-3.19%	-337.41%
APYX	43.7M	52.3M	1.60%	-56.21%	-2.33	0.83	17.61%	19.28%
AEMD	3.9M	3.7M	-13.45%	142.62%	-0.32	1.03	5.77%	8.23%

Accelerate Diagnostics Inc News

Latest updates

Accelerate Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-8.2%	3,027,000	3,299,000	2,921,000	2,812,000	2,973,000	2,960,000	3,861,000	2,958,000	3,344,000	3,122,000	2,798,000	2,518,000	3,110,000	3,588,000	2,125,000	2,342,000	3,470,000	2,271,000	1,806,000	1,750,000	1,822,000
Gross Profit	491.6%	633,000	107,000	799,000	1,011,000	842,000	579,000	1,080,000	802,000	-3,317,000	986,000	1,053,000	897,000	1,149,000	1,301,000	954,000	1,055,000	1,513,000	1,154,000	899,000	834,000	524,000
Costs and Expenses	-23.0%	11,363,500	14,757,000	13,384,000	17,073,000	14,801,500	15,540,000	19,069,000	16,697,000	16,094,000	15,518,000	18,643,000	20,924,000	16,229,500	16,466,000	16,679,000	18,785,000	19,783,000	18,807,000	18,986,000	19,656,000	20,283,000
S&GA Expenses	-25.3%	5,794,000	7,761,000	7,564,000	10,105,000	8,771,500	8,255,000	11,493,000	10,673,000	11,491,500	10,806,000	12,910,000	14,029,000	11,165,000	11,465,000	11,332,000	12,943,000	13,583,500	12,743,000	12,837,000	12,723,000	13,378,500
R&D Expenses	-20.4%	5,569,500	6,996,000	5,820,000	6,968,000	6,030,000	7,285,000	7,576,000	6,024,000	4,602,500	4,712,000	5,733,000	6,895,000	5,064,500	5,001,000	5,347,000	5,842,000	6,199,500	6,064,000	6,149,000	6,933,000	6,904,500
EBITDA Margin	4.4%	-4.76	-4.98	-6.55	-4.89	-4.47	-5.28	-4.42	-4.80	-5.67	-5.71	-6.32	-6.49	-6.35	-	-	-	-	-	-	-	-
Interest Expenses	-	122,000	-	-	-	-	351,500	713,000	1,506,000	-4,095,000	4,211,000	4,177,000	4,090,000	-7,251,500	3,955,000	3,835,000	3,749,000	3,671,000	3,598,000	3,528,000	3,459,000	-16,833,000
Income Taxes	330.2%	563,500	131,000	156,000	-	-77,000	-	-	-	45,000	-	-	-	5,000	-	-	-	-110,500	-239,000	17,000	221,000	-221,000
Earnings Before Taxes	-1294.2%	-12,432,000	1,041,000	-32,579,000	-16,800,000	-14,686,000	-15,896,000	-18,523,000	-13,465,000	-22,758,000	-8,986,000	-21,674,000	-24,239,000	-18,907,000	-18,757,000	-19,230,000	-21,309,000	-21,445,500	-20,673,000	-20,798,000	-21,500,000	-22,412,000
EBT Margin	4.0%	-5.04	-5.25	-6.85	-5.23	-4.91	-5.38	-4.80	-5.47	-6.59	-6.39	-6.96	-7.15	-7.00	-	-	-	-	-	-	-	-
Net Income	-1528.4%	-12,998,000	910,000	-32,735,000	-16,795,000	-14,609,000	-15,896,000	-18,523,000	-13,465,000	-22,803,000	-8,986,000	-21,674,000	-24,239,000	-18,912,000	-18,757,000	-19,230,000	-21,309,000	-21,335,000	-20,434,000	-20,815,000	-21,721,000	-22,191,000
Net Income Margin	3.0%	-5.11	-5.27	-6.86	-5.22	-4.90	-5.39	-4.80	-5.48	-6.59	-6.39	-6.96	-7.15	-7.00	-	-	-	-	-	-	-	-
Free Cashflow	6.0%	-7,755,000	-8,253,000	-10,861,266	-13,473,266	-9,595,266	-13,646,266	-13,072,266	-12,679,266	-12,020,266	-12,521,266	-9,626,266	-13,448,266	-10,416,266	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-20.2%	31.00	39.00	50.00	51.00	65.00	76.00	59.00	70.00	83.00	81.00	94.00	93.00	93.00	104	115	120	134	147	159	172	185
Current Assets	-24.6%	24.00	32.00	42.00	43.00	56.00	66.00	48.00	61.00	73.00	72.00	84.00	82.00	82.00	92.00	103	107	122	134	150	164	178
Cash Equivalents	-39.8%	12.00	20.00	29.00	29.00	35.00	39.00	5.00	14.00	40.00	36.00	45.00	43.00	36.00	27.00	47.00	39.00	61.00	93.00	87.00	75.00	66.00
Inventory	-6.8%	3.00	4.00	5.00	5.00	5.00	5.00	5.00	6.00	5.00	10.00	10.00	10.00	9.00	9.00	9.00	9.00	8.00	8.00	8.00	9.00	8.00
Net PPE	-8.4%	2.00	3.00	3.00	3.00	3.00	4.00	4.00	5.00	5.00	5.00	6.00	6.00	6.00	7.00	8.00	9.00	8.00	9.00	8.00	7.00	7.00
Liabilities	-31.1%	51.00	74.00	89.00	90.00	87.00	86.00	121	126	118	121	164	159	156	154	152	143	142	137	133	129	128
Current Liabilities	-68.2%	12.00	38.00	54.00	68.00	67.00	66.00	67.00	114	7.00	8.00	9.00	7.00	7.00	7.00	10.00	7.00	8.00	6.00	8.00	6.00	8.00
Long Term Debt	-	-	-	-	-	-	-	50.00	9.00	108	110	147	144	141	138	135	133	130	127	125	122	120
LT Debt, Current	0%	1.00	1.00	1.00	57.00	56.00	56.00	56.00	106	-	0.00	1.00	1.00	1.00	1.00	2.00	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	50.00	9.00	108	110	147	144	141	138	135	133	130	127	125	122	120
Shareholder's Equity	-Infinity%	-19.89	-	-	0.00	-22.26	-	0.00	0.00	0.00	-	0.00	0.00	475	-	463	458	-	10.00	26.00	43.00	57.00
Retained Earnings	-2.0%	-668	-655	-656	-624	-607	-592	-576	-558	-570	-547	-538	-517	-492	-474	-455	-436	-414	-393	-372	-352	-330
Additional Paid-In Capital	4.3%	695	666	664	631	630	628	560	547	581	553	514	496	475	469	463	458	452	449	444	440	433
Shares Outstanding	0.4%	15.00	15.00	14.00	10.00	10.00	8.00	7.00	7.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	61.00	-	-	-	53.00	-	-	-	320	-	-	-	480	-	-	-	714	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	5.9%	-7,755	-8,241	-10,833	-13,367	-9,550	-13,573	-12,999	-12,606	-11,947	-12,448	-9,553	-13,375	-10,343	-12,656	-9,798	-17,597	-13,865	-17,367	-14,057	-19,505	-14,326
Share Based Compensation	-24.8%	1,364	1,815	1,653	555	2,446	1,229	3,971	2,979	2,989	3,629	6,590	8,839	4,173	4,676	3,416	4,199	3,209	3,131	2,881	3,397	1,946
Cashflow From Investing	68.9%	-110	-354	915	8,209	5,842	15,788	4,428	-13,641	-2,750	2,789	-257	8,522	17,852	-9,938	11,048	-5,356	-18,653	21,294	25,371	24,799	18,842
Cashflow From Financing	113.1%	107	-817	9,806	-77.00	-126	32,036	-357	77.00	18,891	830	11,650	11,855	1,340	2,255	6,609	1,429	581	1,622	804	3,816	175
Buy Backs	-	-	-	-	-	-	-	-	-	20,294	3.00	-	-	-	-	-	-	-	-	-	-	-

AXDX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net sales	$ 12,059,000	$ 12,752,000	$ 11,782,000
Cost of sales:
Cost of sales of products and services	8,325,000	9,449,000	7,663,000
Inventory write-down	1,184,000	0	4,500,000
Total cost of sales	9,509,000	9,449,000	12,163,000
Gross profit (loss)	2,550,000	3,303,000	(381,000)
Costs and expenses:
Research and development	25,353,000	26,915,000	21,943,000
Sales, general and administrative	31,225,000	39,193,000	49,236,000
Total costs and expenses	56,578,000	66,108,000	71,179,000
Loss from operations	(54,028,000)	(62,805,000)	(71,560,000)
Other (expense) income:
Gain on fair value adjustment	12,955,000	0	0
Foreign currency exchange gain (loss)	71,000	117,000	(413,000)
Interest income	1,123,000	551,000	88,000
Other expense, net	108,000	(227,000)	(20,000)
Total other (expense) income, net	(6,740,000)	235,000	(6,097,000)
Net loss before income taxes	(60,768,000)	(62,570,000)	(77,657,000)
(Provision) benefit for income taxes	(850,000)	77,000	(45,000)
Net loss	$ (61,618,000)	$ (62,493,000)	$ (77,702,000)
Basic net loss per share (in dollars per share)	$ (4.94)	$ (7.61)	$ (12.59)
Diluted net loss per share ( in dollars per share)	$ (4.94)	$ (7.61)	$ (12.59)
Weighted average shares outstanding, basic (in shares)	12,477	8,216	6,173
Weighted average shares outstanding, diluted (in shares)	12,477	8,216	6,173
Other comprehensive loss:
Net loss	$ (61,618,000)	$ (62,493,000)	$ (77,702,000)
Net unrealized gain (loss) on available-for-sale investments	29,000	(14,000)	(34,000)
Foreign currency translation adjustment	(241,000)	(326,000)	(117,000)
Comprehensive loss	(61,830,000)	(62,833,000)	(77,853,000)
Nonrelated Party
Other (expense) income:
Interest expense	(5,926,000)	(2,274,000)	(15,545,000)
(Loss) gain on extinguishment of debt	(6,499,000)	3,565,000	9,793,000
Related Party
Other (expense) income:
Interest expense	(1,817,000)	(1,497,000)	0
(Loss) gain on extinguishment of debt	$ (6,755,000)	$ 0	$ 0

AXDX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 12,138	$ 34,905
Investments	1,081	10,656
Trade accounts receivable, net	2,622	2,416
Inventory	3,310	5,194
Prepaid expenses	380	818
Purchase obligation put option asset	3,419	0
Other current assets	1,516	2,025
Total current assets	24,466	56,014
Property and equipment, net	2,389	3,478
Finance lease assets, net	1,518	2,422
Operating lease right of use assets, net	1,177	1,859
Other non-current assets	1,816	1,242
Total assets	31,366	65,015
Current liabilities:
Accounts payable	4,796	4,501
Accrued liabilities	3,243	2,682
Accrued interest	164	472
Deferred revenue and income, current	1,545	547
Current portion of convertible notes	726	56,413
Finance lease, current	583	1,113
Operating lease, current	977	829
Total current liabilities	12,034	66,557
Finance lease, non-current	262	782
Operating lease, non-current	570	1,545
Deferred income, non-current	1,122	0
Other non-current liabilities	1,164	874
Accrued interest, related-party	0	663
Long-term debt, related-party	0	16,858
Convertible notes, non-current	36,102	0
Total liabilities	51,254	87,279
Commitments and contingencies (see Note 15)
Stockholders' deficit:
Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized with no shares issued and outstanding as of December 31, 2023 and 3,954,546 issued and outstanding on December 31, 2022	0	4
Common stock, $0.001 par value; 450,000,000 common shares authorized with 14,569,500 shares issued and outstanding on December 31, 2023 and 200,000,000 common shares authorized with 9,747,755 shares issued and outstanding on December 31, 2022	14	10
Contributed capital	694,634	630,428
Treasury stock	(45,067)	(45,067)
Accumulated deficit	(668,857)	(607,239)
Accumulated other comprehensive loss	(612)	(400)
Total stockholders' deficit	(19,888)	(22,264)
Total liabilities and stockholders' deficit	$ 31,366	$ 65,015

About Accelerate Diagnostics Inc

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

CEO	Mr. Jack Phillips
WEBSITE	https://acceleratediagnostics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	179

Accelerate Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Accelerate Diagnostics Inc? What does AXDX stand for in stocks?

AXDX is the stock ticker symbol of Accelerate Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Accelerate Diagnostics Inc (AXDX)?

As of Mon Apr 22 2024, market cap of Accelerate Diagnostics Inc is 19.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers. The fair value of Accelerate Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Accelerate Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Accelerate Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether AXDX is over valued or under valued. Whether Accelerate Diagnostics Inc is cheap or expensive depends on the assumptions which impact Accelerate Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXDX.

What is Accelerate Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, AXDX's PE ratio (Price to Earnings) is -0.31 and Price to Sales (PS) ratio is 1.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Accelerate Diagnostics Inc's stock?

In the past 10 years, Accelerate Diagnostics Inc has provided -0.408 (multiply by 100 for percentage) rate of return.